Palliative sedation at the end of life at a tertiary cancer center

Augusto Caraceni, Ernesto Zecca, Cinzia Martini, Giovanna Gorni, Tiziana Campa, Cinzia Brunelli, Franco De Conno

Research output: Contribution to journalArticlepeer-review


Purpose: The aim of this study was to describe the use of palliative sedation (PS) its indications and outcomes in patients followed up till death by an inpatient palliative care consult team (PCCT) at a tertiary cancer center. Methods: All patients referred for 5 years to the PCCT and followed up till death were eligible for the study. Both PCCT recordings and hospital charts were reviewed and a codified assessment was performed. Results: Over a total of 2,033 consecutive consults, 129 patients died during admission and were eligible. Eighty-three had the indication to PS, 4% of all consults (95% confidence interval [95%CI], 3% to 5%) and 64% of eligible patients (95%CI, 56% to 73%). PS was more frequently indicated in males and in patients with recurrent dyspnea and recurrent agitation, while it was less frequently indicated in older people and in patients with cerebral metastases and recurrent drowsiness. The most frequent indications to PS were dyspnea (37%) and delirium (31%) alone or combined with other symptoms. PS was successfully achieved in 69 patients; the drugs most frequently used for PS were midazolam (46%), haloperidol (35%), and chlorpromazine (32%) and opioid dose escalation was higher in sedated patients (P

Original languageEnglish
Pages (from-to)1299-1307
Number of pages9
JournalSupportive Care in Cancer
Issue number6
Publication statusPublished - Jun 2012


  • Cancer
  • End-of-life care
  • Palliative care
  • Palliative sedation

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Palliative sedation at the end of life at a tertiary cancer center'. Together they form a unique fingerprint.

Cite this